Pfizer to discontinue commercialisation of Remoxy for Pain-Pfizer/Pain Therapeutics
Pfizer has notified Pain Therapeutics that it has decided to discontinue its agreement to develop and commercialize Remoxy (oxycodone) Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone for Pain. Pfizer will return all rights, including responsibility for regulatory activities, to Pain Therapeutics. Pfizer has concluded an internal review of the top-line results of five recently completed clinical studies required to address the Complete Response Letter received in June 2011 from the FDA. Pfizer and Pain Therapeutics. will work together for an orderly transition of Remoxy to Pain Therapeutics, Pfizer will continue ongoing activities under the agreement for the next six months until the scheduled termination date.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins